Thieme E-Books & E-Journals -
Zurück
Thromb Haemost 2014; 112(01): 205-215
DOI: 10.1160/TH13-08-0681
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study

Karthik Balasubramaniam
1   Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
,
Girish Viswanathan
1   Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
,
Jeff Dragone
2   Shire Development LLC, Wayne, Pennsylvania, USA
,
Rachael Grose-Hodge
3   Shire Pharmaceuticals Development Ltd., Basingstoke, UK
,
Patrick Martin
2   Shire Development LLC, Wayne, Pennsylvania, USA
,
Steve Troy
2   Shire Development LLC, Wayne, Pennsylvania, USA
,
Peter Preston
2   Shire Development LLC, Wayne, Pennsylvania, USA
,
Azfar G. Zaman
1   Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
4   Cardiology Department, Freeman Hospital, Newcastle upon Tyne, UK
› Institutsangaben